News

Biotech Equity Startup Athari Bio Chooses Loudoun for New Headquarters

Athari Biosciences, a rapid-growth, minority- and woman-owned startup focused on improving equity and inclusion across all facets of healthcare, announced it has selected Loudoun County, Virginia, for its new corporate headquarters.

The project includes a wet lab, a tech lab, research and development and office space and is expected to open in early 2022. The project is expected to create 50 jobs with a total investment of $5 million.

The Loudoun County Board of Supervisors will consider a cash incentive of $120,000 to support the completion of the lab space at its business meeting on December 7, 2021. The incentive has been proposed by Loudoun Economic Development, which worked closely with Athari’s leadership team in the search for the firm’s long-term home, outcompeting multiple locations in Maryland.

“We are very proud to welcome Athari to our innovative business ecosystem at the nexus of health and technology,” Loudoun Economic Development’s Executive Director Buddy Rizer said. “The need for equitable health technology has become evident over the past two years, and Athari’s commitment to Loudoun reinforces the opportunities for innovation in our community.”

Founder and CEO Susan Mitchell is a serial entrepreneur, previously co-founding Guardians of Honor, a grants management, research and evaluation government contract consulting firm. After living in Loudoun County for more than 20 years and serving as a board member for STEM for Her, vice chair of the Loudoun Chamber’s GovCon Committee, and a recently appointed member of Loudoun’s Economic Development Advisory Commission, Mitchell prioritized locating her latest venture in Loudoun.

“The word ‘Athari’ means ‘impact’ in Swahili. Progress happens when we unite the best and brightest minds through a common purpose, and the place to do that is in Loudoun County,” Mitchell said. “Loudoun’s ready access to smart people, wet and tech lab space, and the populations we serve, make it the perfect place for our health equity accelerator.

“Now that we know our ‘where,’ we can work to diversify the ‘who’ and ‘how’ of STEM industries, fixing the problem of underrepresentation and increasing our global health insights.”

According to 2021 research from the Bedford Group, individuals who identify as female represent just 14.2% of biohealth industry leadership, while minorities comprise only 14% of leadership. A lack of representation can also be found in research and development teams, lab technicians and the very datasets that drive medical understanding.

“Healthcare innovation and equity are issues that are very close to my heart, and I’m delighted to have Athari develop tomorrow’s solutions, today in Loudoun County,” Board of Supervisors Chair at Large Phyllis Randall said. “The Athari team is in the business of whole-person wellness, and I applaud their efforts for healthcare rooted in humanity.”

Athari looks to break down silos within the healthcare industry, offering research and development, lab services, education and training as solutions to address health inequity. Services include R&D that positively impacts population health, product commercialization, and pipeline development. Genomic testing, immunodiagnostics, and empowerment through workforce development is just what the doctor ordered.

“As we work to grow and diversify our economy, we view the intersection of health and technology as a unique opportunity to leverage our world-class digital infrastructure,” Supervisor Matt Letourneau (Dulles), Chairman of the Board’s Finance, Government Operations and Economic Development Committee said. “Athari will be well suited to take advantage of Loudoun’s world class workforce and infrastructure to continue to grow, and I thank them for their investment in Loudoun.”

Read more here.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and